Journal article
Lifestyle management of unipolar depression
M Berk, J Sarris, CE Coulson, FN Jacka
Acta Psychiatrica Scandinavica | Published : 2013
DOI: 10.1111/acps.12124
Abstract
Objective: To be used in conjunction with 'Pharmacological management of unipolar depression' [Malhi et al. Acta Psychiatr Scand 2013;127(Suppl. 443):6-23] and 'Psychological management of unipolar depression' [Lampe et al. Acta Psychiatr Scand 2013;127(Suppl. 443):24-37]. To provide clinically relevant recommendations for lifestyle modifications in depression, derived from a literature review. Method: A search of pertinent literature was conducted up to August 2012 in the area of lifestyle factors and depression. A narrative review was then conducted. Results: There is evidence that level of physical activity plays a role in the risk of depression, and there is a large and validated evidenc..
View full abstractRelated Projects (1)
Grants
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The authors wish to thank Dr Sharon Brennan and Ms Shae Quirk for undertaking a systematic review of the diet quality and mental health relationship, some of the results of which informed the narrative review in this paper. J. Sarris and F. Jacka are funded by National Health and Medical Research Council (NHMRC) Research Fellowships (JS: ID 628875, FJ ID: 628912).Professor Michael Berk has received funding for research from Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo Smith K-line, Organon, Novartis, Mayne Pharma, Servier, AstraZeneca; has received honoraria for speaking engagements from AstraZeneca, Bristol Myers Squibb, Eli Lilly, Glaxo Smith K-line, Janssen Cilag, Lundbeck, Organon, Pfizer, Sanofi-Synthelabo, Solvay, Wyeth; and served as a consultant to AstraZeneca, Bristol Myers Squibb, Eli Lilly, Glaxo Smith K-line, Janssen Cilag, Lundbeck, Pfizer. Dr Jerome Sarris is supported by a National Health and Medical Research Council Fellowship (628875). He has received travel and/or speaking remuneration from Integria Healthcare, Society for Medicinal Plant and Natural Product Research, Taki Mai, and Pfizer; and has received consultancy payment from Soho Flordis International. Dr Carolyn Coulson has no funding conflicts to declare. Associate Professor Felice Jacka has received grant/research support from the Brain and Behaviour Research Institute, the National Health and Medical Research Council (NHMRC), Australian Rotary Health, the Geelong Medical Research Foundation, the Ian Potter Foundation, Eli Lilly and The University of Melbourne and has been a paid speaker for Sanofi-Synthelabo, Janssen Cilag, Servier, Pfizer, Health Ed, Network Nutrition and Eli Lilly.